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Abstract
Background—Usage of magnetic resonance imaging (MRI) in newly diagnosed breast cancer 
patients is increasing, despite scant evidence that it improves outcomes. Little is known about the 
knowledge, perspectives, and clinical characteristics of surgeons associated with MRI use.
Methods—Women with early-stage breast cancer undergoing definitive surgery between 7/2013–
8/2015 were identified from the Los Angeles and Georgia Surveillance, Epidemiology and End 
Results (SEER) registries, and asked to name their attending surgeons. The 489 surgeons were sent 
a questionnaire; 77% (n=377) responded. Questions addressing the likelihood of ordering an MRI 
in different scenarios were used to create a scale measuring surgeon propensity for MRI use. 
Knowledge and practice characteristics were also assessed.
Results—Mean surgeon age was 54 years, 25% were female, and median number of years in 
practice was 21. Wide MRI use variation was observed, with 26% obtaining MRI for a clinical 
stage I screen-detected breast cancer and 72% for infiltrating lobular cancer. High users of MRI 
were significantly more likely to be higher-volume surgeons (p<.001) and to have misconceptions 
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about MRI benefits (p<.001). Of surgeons who felt they used MRI more often, 60% were high 
MRI users; only 6% were low MRI users.
Conclusions—Our findings suggest relatively frequent use of MRI, even in uncomplicated 
clinical scenarios, in the absence of evidence of benefit, and use was more common among high-
volume surgeons. A substantial number of surgeons who are high MRI users harbor 
misconceptions about MRI benefit, suggesting an opportunity for education and consensus 
building regarding appropriate use.
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INTRODUCTION
The use of magnetic resonance imaging (MRI) in newly diagnosed breast cancer patients has 
increased dramatically since 20031,2 in spite of a lack of evidence that it improves patient 
outcomes.3 Although MRI finds cancer which is not detected by mammography or 
ultrasound, 2 prospective randomized trials failed to demonstrate a decrease in the use of 
additional surgeries after initial lumpectomy in patients selected for breast-conserving 
surgery (BCS) with MRI4,5, and an individual patient-level metaanalysis showed no impact 
of MRI use on rates of local recurrence in patients having BCS.6 The downsides of MRI are 
well documented and include an increased number of benign biopsies and a higher 
mastectomy rate, as well as increased costs.3,7,8 Despite this, guidelines reference MRI as an 
optional part of the workup of operable breast cancer9, and it remains a commonly used test. 
Little is known about the attributes and perspectives of surgeons who do and do not obtain 
preoperative MRI in newly diagnosed breast cancer patients. The purpose of this study was 
to examine surgeon perspectives regarding clinical circumstances in which MRI is 
beneficial, characteristics of surgeons associated with MRI use, their knowledge regarding 
benefits and harms of MRI, and the influence of patients on the decision to obtain an MRI.
METHODS
Sampling and data collection
The Individualized Cancer Care (iCanCare) study is a population-based survey study of 
early-stage breast cancer patients and their clinicians. Women 20–79 years of age diagnosed 
with ductal carcinoma in situ and stage I and II breast cancer, and undergoing definitive 
surgical therapy were identified using rapid case ascertainment from the Georgia and Los 
Angeles County Surveillance, Epidemiology End Results (SEER) registries between July 
2013 and August 2015. Of the initial 7810 women selected, 7303 were eligible and 5080 
patients responded (70% of those eligible). Virtually all patient respondents (96%) named 
their attending surgeon: 489 surgeons were sent surveys toward the end of the patient data 
collection period, and 377 (77%) responded.
The surgeon questionnaire content was extensively piloted, as done in prior clinician surveys 
conducted by our team10 and included: 1) demographic and practice information; 2) 
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scenario-based queries of attitudes about testing and treatment strategies; and 3) attitudes 
about patient communication and decision making.
Measures
The dependent variable measuring surgeon acceptance of the use of MRI was derived from 
five short clinical scenarios that were presented to surveyed surgeons. Item responses were 
fit with a graded item response model to create a latent scale measuring surgeon perspective 
toward preoperative MRI use.11 The 5 items contributing to the scale were surgeon 
responses to the questions “In general, do you obtain pre-operative MRI for newly 
diagnosed breast cancer patients…” 1) with a cT1N0 mammographically detected mass; 2) 
who are ≤ 45 years of age; 3) with a biopsy showing infiltrating lobular cancer; 4) with 
estrogen receptor negative, progesterone receptor negative, HER2 negative (triple-negative) 
cancers; and 5) who are ≥ 70 years of age. Item responses to each question included 
“definitely yes”, “probably yes”, “probably no”, and “definitely no”. The composite MRI 
propensity scores were normally distributed and were divided into high (n = 93), selective (n 
= 180), and low (n = 86) MRI usage groups using the outer quartiles of the score 
distribution. Scores were calculated for 359 of the 377 responding surgeons; 17 surgeons did 
not respond to any of the MRI items and 1 surgeon responded uniquely such that a score 
could not be calculated.
The relationship between surgeon MRI propensity and SEER site, number of years in 
practice, breast cancer patient volume, and MRI misconceptions held by the surgeon was 
examined. Surgeon knowledge regarding the clinical utility of MRI was assessed by asking: 
1) If preoperative MRI decreases the need for re-excision in patients having BCS; 2) If 
preoperative MRI reduces the risk of local recurrence in patients having BCS; and 3) If 
preoperative MRI increases the likelihood of having a mastectomy (Table 1). Answering 
“definitely yes” or “probably yes” to either of the first 2 questions was scored as a 
misconception based on published literature5–7,12, while responding “definitely no” or 
“probably no” to the mastectomy question was scored as a misconception.5,7 Wrong answers 
were aggregated to determine the total number of misconceptions held by a surgeon.
We examined the role of patients in MRI decision making by asking surgeons how often 
their patients initiated a request for MRI and how often the surgeon involved patients in the 
decision about whether to order an MRI. Responses for these items were “never”, “rarely”, 
“sometimes”, “often” and “always”. Surgeons were also asked whether they thought they 
used MRI less often, about the same as, or more often than other surgeons treating breast 
cancer in their community.
Statistical Methods
We first described surgeon demographic and practice factors of interest (Table 2). We then 
examined surgeon report of their use of MRI for each clinical scenario. We evaluated the 
relationship between annual breast cancer patient volume for surgeon respondents, 
propensity for MRI, and MRI misconceptions. A proportional odds logistic regression was 
used to model the relationship between surgeon MRI propensity (low/selective/high MRI 
utilization) and surgeon characteristics of site, number of years in practice, and breast cancer 
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patient volume. The score test did not reject the assumption of proportional odds. Finally, we 
examined the interplay between the MRI propensity groups and surgeons report of their use 
of MRI relative to surgeons in the community. All analyses were conducted using SAS 
Version 9.4 (Cary, NC, USA). PROC LOGISTIC was used for ordinal logistic regression.
RESULTS
The characteristics of the 377 responding surgeons are summarized in Table 2. The mean 
surgeon age was 54 years (range 31–80) and 25% were female. The median number of years 
in practice was 21. Of responding surgeons, 84% reported that they devoted more than 40 
hours per week to clinical patient care, and 23% of the new patients seen by the surgeon 
sample had breast cancer. Practice volume was varied, with 39% of surgeons seeing 20 or 
fewer new breast cancers annually, and 30% seeing 51 or more. Differences in practice 
volume on the basis of gender were also observed. Although female surgeons made up only 
25% of the study participants, they accounted for 52% of the high-volume surgeons. Practice 
setting was also varied, with 51% of respondents seeing patients in more than 1 hospital, and 
30% having residents or fellows in their primary practice.
There was substantial variation in surgeon report of their use of MRI for different clinical 
scenarios (Fig. 1). One quarter (26%) of surgeons would definitely or probably order an 
MRI for a clinical stage I screen-detected breast cancer. In contrast, 54% to 72% of surgeons 
would order an MRI for a woman age ≤ 45 years with breast cancer or one with lobular 
carcinoma or triplenegative breast cancer. The scenario least frequently associated with MRI 
use (10%) was women 70 years of age or older. Over half (51%) of surgeons reported that 
their patients never or rarely initiated a request for an MRI, and only 9% reported that 
patients often or always requested the test. Thirty percent of surgeons indicated that they 
never or rarely involved patients in the decision about whether to order an MRI, 32% shared 
the decision sometimes, and 38% often or always sought patient involvement.
As shown in Fig. 2, high-volume surgeons were substantially more likely to be high users of 
MRI than their lower-volume counterparts when using ordinal logistic regression to adjust 
for site, years in practice, and gender. After marginal standardization13, 35% of surgeons 
treating more than 50 breast cancer patients annually were high MRI users, while only 18% 
of surgeons seeing 20 or fewer breast cancer patients were high MRI users. Conversely, 
high-volume surgeons were much less likely to be low MRI users, while no relationship 
between volume of breast cancer cases and selective use of MRI was observed. Regression 
results indicate that surgeons seeing more than 50 breast cancer patients annually were 2.6 
times (95% confidence interval [CI] 1.5–4.5) more likely than those seeing less than 20 
breast cancer patients to be in the high MRI-use group. Similarly, females were 2.7 times 
(95% CI 1.5–4.8) more likely than males to be in the high MRI-use group. Lastly, for every 
10 additional years in practice, a surgeon was 1.2 times (95% CI OR 1.0–1.5) more likely to 
be in the high MRI-use category.
Of the 343 surgeons who answered all 3 questions about the utility of MRI, 76% (n = 259) 
incorrectly answered 0 or 1 out of 3 questions (misconception count of 0 or 1), 58 (17%) had 
a misconception count of 2, and 19 (6%) had a misconception count of 3. The questions 
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regarding MRI impact on re-excision, local recurrence, and mastectomy were answered 
incorrectly by 29%, 18%, and 41% of responding surgeons, respectively. MRI use was also 
associated with misconceptions about the test. As the tendency to use MRI increased from 
low to high, the proportion of surgeons with 2 or 3 misconceptions increased from 8% to 
40% (Fig. 3, p < 0.001). Interestingly, surgeons had a high level of awareness regarding how 
their use of MRI compared with that of their peers: high-use surgeons comprised 60% of the 
group who responded that they ordered MRI more frequently than their peers, versus 6% of 
low-use surgeons (Fig. 4, p < 001), and only 4% of high MRI use surgeons felt that they 
ordered MRI less often than their peers.
DISCUSSION
Our results suggest that the decision to obtain an MRI in newly diagnosed breast cancer 
patients is surgeon driven, as fewer than 10% of surgeons indicated that their patients often 
initiate a request for the study. In this heterogeneous surgeon sample, the propensity to order 
MRI in different clinical scenarios varied widely, ranging from 10% to 72%. This likely 
reflects the general lack of consensus among surgeons surrounding the benefit of 
preoperative MRI. Two prospective randomized trials have failed to demonstrate a reduction 
in the number of additional surgeries after initial lumpectomy in patients selected with 
MRI4,5, while a third showed a decrease in re-excision rate which was balanced by an 
increase of the same magnitude in initial mastectomies.14 Single-institution retrospective 
studies12,15 and an individual patient level meta-analysis6 show no decrease in locoregional 
recurrence in patients having preoperative MRI. In spite of this, guidelines promulgated by 
breast imaging societies continue to endorse MRI for preoperative staging of the ipsilateral 
and contralateral breast16, although radiologists acknowledge that the level of consensus on 
its use in patients with infiltrating ductal carcinoma undergoing surgery as the initial step in 
treatment is low.17 The lack of consensus on the benefit of routine preoperative MRI is also 
evident among the surgeons in our study, with 26% endorsing MRI for preoperative 
evaluation of a patient with an uncomplicated clinical stage I screen-detected cancer. A 
substantially greater proportion, 72%, favored MRI in patients with infiltrating lobular 
cancer, an entity known to be underestimated by mammography, and the clinical scenario 
with the greatest number of studies suggesting benefit for preoperative MRI.7,18,19 The 
enthusiasm for MRI in younger women and those with triple-negative breast cancer is 
somewhat more difficult to justify based on data. While these patients are known to have 
higher rates of local recurrence after breast-conserving therapy than their older, or non-triple 
negative counterparts, they also have an increased incidence of local recurrence after 
mastectomy, suggesting that recurrence is due to aggressive tumor biology.20–22 In the 
setting of increased local recurrence after both breast-conserving surgery and mastectomy, 
MRI detection of subclinical disease is unlikely to alter outcomes.
When all clinical scenarios were grouped together, we identified a strong relationship 
between practice volume and the tendency to order MRI after adjusting for site, years in 
practice, and gender, whereby surgeons treating a higher volume of breast cancer cases 
would be more likely to obtain an MRI. This may reflect greater access to MRI in higher-
volume practices, something we did not assess in this survey. A recommendation for an MRI 
is often provided by the radiologist interpreting the patients’ mammograms, and it is likely 
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that radiologists practicing in higher-volume centers with MRI capability would be more 
likely to recommend the test than those in lower-volume practices. We also identified 
misconceptions regarding the benefits of MRI in a significant number of surgeons, and these 
misconceptions were much more common among surgeons with a greater propensity to 
order MRI. This may reflect doctors adjusting their attitudes about the benefits of a test in 
the context of a practice factor that favors it use.
Our study has a number of strengths. We surveyed a diverse sample of surgeons treating a 
population-based cohort of breast cancer patients in a very recent time period. The response 
rate to our survey was extremely high, and we were able to examine both practice attributes 
and surgeon attitudes. However, there were weaknesses. We relied upon surgeon report of 
when they would order an MRI and did not have actual utilization data. Some surgeons 
might disagree with our classification of misconceptions. However, randomized trials and 
meta-analyses support these as being misconceptions, and incorrect answers were distributed 
across all 3 statements.
Our findings have important implications for patient care and policy. Breast MRI has been 
reimbursed by Medicare and other payers for patients with newly diagnosed breast cancer 
since 1991, but its clinical use has only become widespread in the past 10 years.1,2,23 In 
addition to the cost of the MRI itself, its use may generate additional costs due to biopsies24, 
short interval follow-up examinations, and patient preference for mastectomy rather than 
breast-conserving therapy.25 Our finding that over a quarter of surgeons would definitely or 
probably order an MRI for a clinical stage I screen-detected breast cancer suggests relatively 
frequent indiscriminate use of this procedure, and, alarmingly, that those who favor this 
approach are those surgeons who themselves see the largest volume of breast cancer 
patients. Misconceptions regarding test benefits tend to be more common among low-
volume practitioners who lack experience in a subspecialty; the frequency with which we 
observe misconceptions in high-MRI users is particularly concerning. Our findings suggest 
an opportunity to educate individual surgeons to reduce the use of MRI, as even many high-
volume breast specialists appear to harbor misconceptions about the benefits of testing when 
evidence is clearly lacking. These surgeons tend to be breast specialists at higher-volume 
centers and appear to be aware of their higher test use relative to others in the community. 
These surgeons may be more easily identified through their specialty societies to engage 
them in building consensus about the role of MRI after diagnosis of breast cancer.
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Synopsis
In the setting of newly diagnosed breast cancer patients, wide variation in MRI use was 
observed. High users were significantly more likely to be high-volume surgeons and to 
have misconceptions about MRI benefits.
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Fig. 1. 
Surgeon attitudes about MRI use as indicated by surgeon response to 5 MRI scenarios. All 
indicated scenarios were prefaced with “In general, do you obtain pre-op MRI for newly 
diagnosed breast cancer patients…with/who are”. Allowable responses to each scenario 
were “definitely yes”, “probably yes”, “probably no”, or “definitely no”
cT1N0, clinical stage I; ER, estrogen receptor; PR, progesterone receptor
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Fig. 2. 
Distribution of surgeon MRI propensity (high, selective, or low) by surgeon volume, 
adjusted for gender, years in practice, and SEER site. Surgeon volume was reported as the 
number of new patients seen in the past 12 months who were diagnosed with breast cancer
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Fig. 3. 
Relationship of MRI misconceptions to surgeon MRI propensity (high, selective, or low). 
Physicians who incorrectly answered 2 or more of 3 MRI-use questions were classified as 
having MRI misconceptions
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Fig. 4. 
Relationship of surgeon MRI propensity (high, selective, or low) to their perceived MRI 
usage (less often, about the same, more often) relative to other breast surgeons in the 
community
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Table 1
MRI Knowledge Questions
1. Pre-op MRI decreases the need for re-excision in patients undergoing breast-conserving surgery (BCS).
2. Patients selected for BCS with MRI have a lower rate of local recurrence at 5 years than those selected with mammography +/− ultrasound.
3. The likelihood of having a mastectomy is significantly increased in women having pre-op MRI compared to those who do not.
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Table 2
Surgeon sample characteristics (n = 377)
Characteristic Percent or Mean (range)
Age at survey administration (n = 360) 53.7 years (31–80)
Gender
  Female 24.4%
  Missing 1.9%
SEER site
  Los Angeles County 50.1%
  Georgia 49.9%
Surgeon volume (Breast cancer patients in prior 12 months)
  0–20 37.7%
  21–50 29.7%
  > 50 28.9%
  Missing 3.7%
Surgeon years in practice (n = 372) 20.8 (0–45)
Number of hospitals seeing patients
  1 47.5%
  2 31.0%
  3 or more 18.6%
  Missing 2.9%
Working with Resident or Fellows
  Yes 29.2%
  Missing 1.9%
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